Group 1F: Breast Cancer—Liver Metastasis; Liquid Biopsy



Thursday, June 9
10:00 am – 11:30 am Eastern Time (US/New York)



Mentor: Janice Cowden, R.N.

Janice was diagnosed with Stage IV metastatic triple-negative breast cancer in 2016, a recurrence from Stage I tnbc nearly 5 years prior. An exceptional responder to her first line of treatment, Janice is extremely fortunate to have had no evidence of disease (NED) since November 2016. With a 20+ year background in Nursing, science, research and studying diseases have always been of interest. Nine months following her MBC diagnosis, Janice launched into MBC Patient Advocacy by participating in training through Living Beyond Breast Cancer’s (LBBC) Hear My Voice Advocacy Outreach program in 2017. As a Research Advocate, Janice attends multiple scientific breast cancer conferences annually to learn more about MBC research and disease. She has a strong interest in partnering with Scientists, Researchers, and Clinicians to work towards more effective treatment modalities that enable MBC patients to live longer and provide a better quality of life. In 2019, she completed NBCC’s Project LEAD. Predominantly, Janice’s advocacy interests include MBC education, awareness, & research, legislative/policy, as well as Peer-to-Peer support. She is a trained Peer Support Volunteer Leader for METAvivor Research & Support and serves as a Peer mentor for LBBC’s volunteer Helpline, as well as for ABCD. Janice is involved in several patient-led advocacy groups, including GRASP, the Patient Centered Dosing Initiative (PCDI), ACE Collaborative Group, the Love Army Research Scientific Advisory Committee, and is the founder and Administrator of The Newly Diagnosed MBC Facebook Peer Support group. She considers herself a lifelong learner and enjoys educating others. In her spare time, Janice enjoys reading, swimming, and spending time with her family, including three grandchildren.

Twitter: @JaniceTNBCmets

Scientist: Tatiana Prowell, M.D.

Dr. Tatiana Prowell is breast cancer scientific liaison in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA) and associate professor of oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center. She was the principal architect of the FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and was a member of the Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group.

She is a three-time recipient of the FDA’s Excellence in Communication Award, as well as a Giants of Cancer Care Award finalist. A passionate medical educator and mentor, she currently serves on the faculty of the Vail Methods in Clinical Cancer Research Workshop, the Accelerating Anti-Cancer Agent Development and Validation (AAADV) Workshop, the FDA/ASCO Fellows’ Day Workshop, the Society for Translational Oncology Fellows’ Forum, and the Dana Farber Clinical Investigator Seminar Series, among others. She sees patients in the Johns Hopkins Second Opinion Breast Cancer Clinic and teaches in the medical school and medical oncology fellowship training program.

Twitter: @tmprowell